Sma, Available in Italy New Formula Risdiplam Tablets
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.8 Articles
8 Articles
Research and the arrival of new therapies have changed the scenario in the management of spinal muscle atrophy (Sma) opening new perspectives for people who live with the disease. The evolution of treatments, such as the new formulation in tablets of risdiplam, now available also in Italy, in addition to restoring quality and autonomy to daily life, facilitates the continuity of treatment. These are the themes at the center of the event "Brunch …
canaledieci.it
newsbiella.it(Adnkronos) - “Having a tablet therapy guarantees remarkable maneuverability: it is something that you can safely put in your backpack and that allows us to live our daily lives. This means being able to organize for a last-minute trip or avoid having to stop for days to administer the therapy, interrupting the study, the [...]
(Adnkronos) "C" is a before and after in the history of spinal muscle atrophy (Sma). Until a few years ago, especially in the most severe forms, a diagnosis meant confronting a progressive pathology and life prospects of a few years. Today the scenario is profoundly different: people born with the Sma can become adults,... Read more L'articolo Sma, disponibile in Italia nuova formulatura risdiplam in tableti proviene da Cinque Colonne Magazine.
Rec News | Lontani dal mainstream
(Adnkronos) "C" is a before and after in the history of spinal muscle atrophy (Sma). Until a few years ago, especially in the most severe forms, a diagnosis meant confronting a progressive pathology and life prospects of a few years. Today the scenario is profoundly different: people born with Sma can become adults, [...] L'articolo Sma, disponibile in Italia nuova formulatura risdiplam in tableti proviene da Rec News.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
